The efficacy of the ribonucleotide reductase inhibitor didox in preclinical models of AML

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Cook, Guerry J ^a   Caudell, David L ^a   Elford, Howard L ^b   Pardee, Timothy S ^a,c  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b Molecules for Health   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; DNA; GLUCOSE; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; 3,4-DIHYDROXYBENZOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CANCER SURVIVAL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DNA DAMAGE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; ENGRAFTMENT; ENZYME INHIBITION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MIDDLE AGED; MORPHOLOGY; MOUSE; NONHUMAN; PROTEIN INDUCTION; TUMOR VOLUME; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MORTALITY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXAMIC ACIDS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RIBONUCLEOTIDE REDUCTASES; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84913573629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112619     Document Type: Article

References (40)

1. Howlader NA, Krapcho M, Neyman N, Aminou R, Waldron W, et al., eds. (2011) SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute.
2. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, et al. (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108: 63-73.
3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474.
4. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, et al. (2010) A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 116: 971-978.
5. Alibhai SM, Leach M, Minden MD, Brandwein J (2009) Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 115: 2903-2911.
6. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894-1907.
7. Longo DL (2012) Harrison's principles of internal medicine. New York: McGraw-Hill.
8. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6: 232-238.
9. Ferrara F, Palmieri S, Mele G (2004) Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89: 998-1008.
10. Gilliland DG, Jordan CT, Felix CA (2004) The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program: 80-97.
11. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, et al. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109: 1114-1124.
12. Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, et al. (2012) RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 119: 5229-5238.
13. Klisovic RB, Blum W, Wei X, Liu S, Liu Z, et al. (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14: 3889-3895.
14. Cory JG, Cory AH (1989) Inhibitors of ribonucleoside diphosphate reductase activity. New York: Pergamon Press. ix, 273 p. p.
15. Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, et al. (2002) Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res 56: 167-181.
16. Kaul DK, Kollander R, Mahaseth H, Liu XD, Solovey A, et al. (2006) Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. Microcirculation 13: 489-497.
17. Gallaugher LD, Henry JC, Kearns PN, Elford HL, Bergdall VK, et al. (2009) Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model. Comp Med 59: 567-572.
18. Veale D, Carmichael J, Cantwell BM, Elford HL, Blackie R, et al. (1988) A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72.
19. Grusch M, Fritzer-Szekeres M, Fuhrmann G, Rosenberger G, Luxbacher C, et al. (2001) Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp Hematol 29: 623-632.
20. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, et al. (2009) Mouse models of human AML accurately predict chemotherapy response. Genes Dev 23: 877-889.
21. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, et al. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109: 3400-3408.
22. Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, et al. (2006) Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol 135: 52-61.
23. Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, et al. (2000) Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 65: 23-31.
24. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157.
25. Pardee TS (2012) Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLOS One 7: e43185.
26. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, et al. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108: 3898-3905.
27. Elford HL, Wampler GL, van't Riet B (1979) New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39: 844-851.
28. Wang LM, Lu FF, Zhang SY, Yao RY, Xing XM, et al. (2012) Overexpression of catalytic subunit M2 in patients with ovarian cancer. Chin Med J (Engl) 125: 2151-2156.
29. Matsusaka S, Yamasaki H, Fukushima M, Wakabayashi I (2007) Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. Chemotherapy 53: 36-41.
30. Okamura H, Kamei T, Sakuma N, Hanai N, Ishihara T (2003) Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions. Acta Cytol 47: 209-215.
31. Inayat MS, El-Amouri IS, Bani-Ahmad M, Elford HL, Gallicchio VS, et al. (2010) Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox. Journal of Inflammation-London 7.
32. Horvath Z, Hochtl T, Bauer W, Fritzer-Szekeres M, Elford HL, et al. (2004) Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. Cancer Chemother Pharmacol 54: 139-145.
33. Mathews CK (2006) DNA precursor metabolism and genomic stability. FASEB J 20: 1300-1314.
34. Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, et al. (2010) Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLOS One 5: e12405.
35. Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29: 448-457.
36. Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, et al. (2012) Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLOS One 7: e37203.
37. Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental Hematology 29: 448-457.
38. Mayhew CN, Phillips JD, Greenberg RN, Birch NJ, Elford HL, et al. (1999) In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17: 345-356.
39. Takeda E, Weber G (1981) Role of Ribonucleotide Reductase in Expression of the Neoplastic Program. Life Sciences 28: 1007-1014.
40. Benhar M, Dalyot I, Engelberg D, Levitzki A (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Molecular and Cellular Biology 21: 6913-6926.